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ABSTRACT 
Objective: Oral administration of bromelain can decrease its bioactivity once it makes contact with stomach acid. Therefore, bromelain was loaded 
into alginate (Alg), pectin (Pec), and alginate-pectin (AP) beads to control its release into the intestines and avoid degradation. 
Methods: Crude bromelain was purified by ammonium sulfate precipitation and the dialysis process. In vitro releases and kinetics studies of 
bromelain-loaded alginate-pectin beads were carried out using an acid and phosphate buffer medium. The beads were characterized using physical 
analysis, Fourier-Transform Infrared Spectroscopy (FTIR) analysis, and Differential Scanning Calorimetry (DSC) analysis.  
Results: The dialysis fraction of bromelain has a specific activity of 67.93 U/mg, 3.05 times that of crude bromelain. That fraction was encapsulated 
in Alg, Pec, and AP beads with a range of encapsulation efficiency around 82.70–91.39%. Bromelain-loaded pectin and AP19 beads were chosen to 
study in an in vitro release based on their swelling properties and encapsulation efficiency. Bromelain-loaded AP19 beads have lower release than 
bromelain-loaded pectin beads in both dissolution mediums. The cumulative releases of AP19 are 9.99 and 87.81% in 0.1 N HCl and phosphate 
buffer medium, respectively. Bromelain-loaded P and AP beads both follow the zero-order kinetics model and the dissolution mechanism of the 
beads is non-Fickian with a combination of diffusion and erosion. The in vitro antiplatelet activity of dissolution aliquots (20.51 and 18.48%) is 
lower than its dialysis fraction (56.04%). 
Conclusion: This in vitro research data shows promising potency for AP as a carrier for oral administration of bromelain as an antiplatelet agent. 
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INTRODUCTION 
Cardiovascular disease (CVD) is the most widely recognized cause of 
death for people of all ages. It caused 17.9 million deaths in 2016, 
representing 31% of all global deaths. Heart attack and stroke take 
about 85% of these deaths [1]. Cerebrovascular strokes and 
cardiovascular attacks can be triggered by the rupture of vulnerable 
plaques in atherosclerosis and thrombotic processes [2, 3]. The 
fundamental processes in the development of atherothrombosis are 
inflammation and thrombosis which platelets act as a bridge in those 
processes [2, 4]. In general, the pathogenies of thrombus formation 
are platelet activation, subsequent adhesion, the release of granule 
content, and platelet aggregation [2, 5]. The multiple mechanisms 
and side effects of commercial drugs make the researcher thought 
that natural bioactive compounds are very useful to prevent or 
complementary antiplatelet therapy.  
One natural product with therapeutic advantages is bromelain. 
Bromelain is a proteolytic enzyme contained in pineapple plants and 
can act as an anticoagulant, antibiotic, anti-inflammatory, and 
antiplatelet [6]. Oral consumption of bromelain can reduce its 
biological activity due to contact with gastric fluids that have low 
acidity. In the in vitro study, bromelain activity significantly reduced 
in the artificial gastric fluid after the first four hours [7, 8], while 
bromelain can absorb into the intestine without losing its biological 
activity [9]. Hence, the bromelain must be encapsulated to prevent it 
from making contact with gastric fluid in the GI tract. 
Natural biopolymers are a commonly used compound in intestinal 
drug delivery systems. One of these is a polysaccharide that has pH-
responsive properties. The formation of a polyelectrolyte complex 
between alginate and pectin is an interesting thing to develop as a 
drug carrier. Complex forming of alginate-pectin with a simple 
calcium ion gelation method has been reported as an intestinal drug 
delivery system due to its pH-dependent properties [10]. The 
combinations of alginate-pectin show stability as carriers due to 
strong synergic effects in acidic conditions, which increase its 
encapsulation efficiency [11]. Therefore, alginate-pectin beads are 
used as the bromelain carrier in this research. In vitro dissolution of 
bromelain isolated from pineapple cores loaded alginate-pectin 
beads was evaluated in 0.1 N HCl and buffer phosphate pH 6.8 
medium. The kinetics and antiplatelet activity of the dissolution 
aliquots obtained were studied.  
MATERIALS AND METHODS 
Materials 
The bromelain source in this experiment was isolated from 
pineapple that was purchased from a traditional market in Jakarta. 
Sodium alginate was purchased from the Kimica Corporation, pectin 
from CPKelco, commercial bromelain and ADP from Sigma, and the 
other chemicals were bought from Merck.  
Isolation, ammonium sulfate precipitation, and dialysis of 
bromelain 
The isolation, ammonium sulfate precipitation, and dialysis of 
bromelain from the pineapple cores were conducted by the 
previously mentioned method with slight modifications [7]. The 
precipitation process was changed; ammonium sulfate precipitation 
was used at a concentration of 60%, and centrifugation speed was 
increased to 8000 rpm.  
Determination of specific activities 
Specific activities of bromelain were determined by dividing total 
proteolytic activity (U) with total protein contents (mg). The 
proteolytic activities were determined according to the Kunitz 
method with modification on phosphate buffer (pH 7) and 
temperature incubation of 50 °C [12]. While the total protein 
contents were measured using UV-Vis spectrophotometry at 750 nm 
using the Lowry method [13]. 
Synthesis of crosslinked alginate (Alg), pectin (Pec), and 
alginate-pectin (AP) beads 
Sodium alginate or pectin beads were synthesized by mixing 
biopolymer powder (table 2) with 100 ml of fresh distilled water. 
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The mixture was stirred at 400 rpm until homogenous and sonicated 
(Alstron, ALD-40050-18H) at 40 kHz for 15 min to remove air 
bubbles. The homogenous solution was dropped into 100 ml calcium 
chloride solution (5%) using a 24G syringe needle Terumo. The 
alginate beads were continuously stirred for 30 min to produce 
stable beads. The beads were collected and washed twice with 
distilled water to remove excess calcium chloride from their 
surfaces. The obtained beads were air-dried for around 24 h. The 
alginate-pectin beads were synthesized by mixing various formulas 
of alginate and pectin into 100 ml of distilled water (table 2). The AP 
beads were prepared using the ionotropic gelation method as 
mentioned above. Bromelain-loaded hydrogel beads were 
conducted by addition 100 mg of bromelain obtained from isolation 
to the mixture before the ionotropic gelation process.  
Determination of beads size, density, and morphological 
surface analysis 
The bead’s size was measured using a stereomicroscope (Boeco, 
Germany). The size of 100 beads was randomly selected for each 
formula and then the results reported as mean±standard deviation. 
The determination of bead density was conducted by dividing a 
bead’s mass by its volume. The morphological characterization of 
the beads was conducted using scanning electron microscopy (SEM) 
(EVO 50, ZEISS, UK), and the images were captured at various 
magnifications.  
Fourier-transform infrared spectroscopy (FTIR) characterization 
Each powder of sample beads was mixed with potassium bromide 
(KBr) at a ratio of 1:9 and ground until homogeny was reached. The 
sample was placed into a sample holder, and the spectral was taken 
at a range of 4000–400 cm-1 with a resolution of 2 cm-1 using FTIR 
spectroscopy (Shimadzu IRPrestige-21). 
Differential scanning calorimetry (DSC) 
DSC of beads was performed by DSC-60A (Shimadzu). The sample 
was weighed 25 mg and scanned in an aluminum pan over a 
temperature range of between 50 and 350 °C at a scan rate of 10 
°C/min in the air atmosphere. 
Determination of swelling ratio of the beads 
The swelling ratio study was conducted by weighing a mass of dry 
beads (md) and then soaking it in different solutions; there are 0.1 N 
HCl and phosphate buffer pH 6.8 for 30 min at room temperature. 
Excess water on the hydrogel beads’ surface was removed using 
filter paper and then weighed (mw). The swelling ratio was 
calculated using the following equation [14]. 
%Swelling ratio = 
mw− md
md
 × 100% 
Determination of encapsulation efficiency 
100 mg of each type of bromelain-loaded hydrogel beads was 
crushed. The crushed beads were soaked in 100 ml of phosphate 
buffer (pH 7.4), kept overnight, which was followed by 15 min of 
sonication. The remaining debris in the solution was removed using 
filtering paper [14]. The bromelain content was measured by using a 
spectrophotometer at 280 nm with BSA solution as a standard. The 
efficiency of encapsulation of bromelain was calculated using the 
following equation [15].  
The efficiency of encapsulation = 
Actual bromelain content in beads 
Theoretical bromelain content in beads 
 × 
100% 
In vitro dissolution and its kinetics study 
The in vitro dissolution of beads was carried out using a USP 
dissolution apparatus, I-Basket type (Electolab TDT-08L). The 
condition of the dissolution was at temperature 37±0.5 °C under 100 
rpm speed. Bromelain-loaded beads were weighing one gram and 
put into the basket. The basket was immersed into 750 ml of 0.1 N 
HCl for 2 h, and then 250 ml of 0.2 M sodium phosphate tribasic was 
added into the system and continuously stirred for 45 min. The 
amount of 10 ml of aliquots was taken at regular time intervals, and 
the same amount of fresh medium was added into the system. The 
obtained aliquots were filtered and the absorbance measured using 
UV-Vis spectrophotometry (Shimadzu UV-2450) at 280 nm with BSA 
solutions as a standard [15]. The in vitro dissolution data was 
analyzed using various kinetic equations, such as zero-order, first-
order, Higuchi, and Korsmeyer-Peppas. The correlation coefficient 
(R2) and constant (k) values were obtained from regression analysis 
of linear curve plotting while the release mechanism was 
determined by the diffusion exponent ‘n’, which was obtained from 
the Korsmeyer-Peppas plot of initial 60% of the cumulative release 
of bromelain [14].  
In vitro antiplatelet activity 
The determination of antiplatelet activity was conducted by mixing 
70 µl of the sample, 560 µl of platelet-rich plasma (PRP), and 3.3 ml 
of saline solution. The mixture was shaken using a vortex and then 
incubated for 10 min at 37 °C; absorbance was measured using UV-
Vis spectrophotometry at 600 nm (Abefore). Next, to trigger the 
aggregation of PRP, 70 µl ADP 5µM was added into the mixture, 
which was incubated for 10 min at 37 °C. The absorbance of the final 
mixture was measured using UV-Vis spectrophotometry at 600 nm 
(Aafter). In this step, water was used as a negative control (NC), while 
cilostazol and aspirin (1 mg/ml) used as positive controls (PC). The 
percentages of platelet aggregation and antiplatelet activity were 
calculated using the following formula [12]: 
Percentage of platelet aggregation = (1 −
Aafter
Abefore
) × 100% 
Percentage of antiplatelet activity = 
%Aggregation of negative control − %Aggregation of sample
%Aggreagation of negative control
× 100% 
RESULTS AND DISCUSSION 
Isolation, ammonium sulfate precipitation, and dialysis of 
bromelain 
The isolation process was carried out via the centrifugation of pineapple 
cores juice at 8000 rpm in temperature conditions of±4 °C for 15 min. 
This process aims to separate crude bromelain solution from other solid 
pineapple fibers. In order to concentrate the protein, ammonium sulfate 
precipitation with a final saturation of 60% was added to the crude 
bromelain solution. The precipitation of protein occurred during the 
salting-out process. At that ammonium salt saturation level, protein-
protein interactions will be stronger than protein-solvent interactions, 
which trigger protein molecules to make an aggregate with lower 
solubility. The bromelain aggregate can be separated from the solution 
with centrifugation in the same condition as above. 
  
Table 1: The specific activity of bromelain in each purification step 







Proteolytic activity (U) Protein (mg) 
Crude bromelain (CB) 208355.70 9387.00 22.20±0.11 1.00 100 100 
Ammonium sulfate 60% 
fraction (F60) 
29966.44 632.63 47.37±0.11 2.12 14.32 6.74 
Dialysis fraction (DF) 36434.00 536.35 67.93±0.21 3.05 17.41 5.71 
Remaining fraction (RF) 62416.11 7927.50 7.87±0.17 0.35 29.18 84.45 
*Data represented as mean±SD (n=3) 
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This process increases the protein levels in bromelain, which is in 
line with its proteolytic activity. The ammonium sulfate in bromelain 
was removed by dialysis using a membrane with 14 kDa pores 
which smaller than bromelain molecules (23-36 kDa) [16]. The 
difference in the concentration of phosphate buffer of the dialysis 
system and bromelain causes the diffusion process to occur. The 
ammonium sulfate and small proteins in bromelain will move 
through the dialysis membrane into the phosphate buffer with a 
lower concentration. The dialysis process will stop when the 
concentration of phosphate buffer reaches equilibrium. This process 
will decrease the protein content level and increase the proteolytic 
activity of the bromelain. The specific activity data of the bromelain 
is shown in table 1. As shown in the FTIR spectrum in fig. 1, 
bromelain has OH and NH overlapping bands at 3700–3000 cm-1. A 
peak of 1660 cm-1 indicates a strong intensity of C=O stretch (amide 
I area), and a C–N stretch band appears at 1546 cm-1 [17]. 
Synthesis of bromelain loaded−alginate (Alg), pectin (Pec), 
alginate-pectin (AP) beads 
Beads were formed by dropping alginate, pectin, or alginate-pectin 
solution into calcium chloride solution. The presence of the Ca2+ion 
triggers an ionic crosslink between the anionic guluronic unit in the 
alginate and the galacturonic unit in the pectin to form an egg box 
conformation. Various divalent ions can lead to an egg box 
confirmation with an anionic biopolymer such as Pb2+, Cu2+, Ba2+, and 
Sr2+. The calcium ion was used in this research because it does not 
inhibit bromelain activity. The FTIR spectra of sodium alginate, pectin, 
placebo alginate-pectin, and bromelain-loaded alginate-pectin with 
KBr were taken at wavenumber 4000–400 cm-1 and resolution 2 cm-1. 
Fig. 1 shows some characteristic bands elucidating interaction and 
fingerprint for biopolymers. Overall, there are five regions proposed in 
the spectrum, at ranges 3800–3000 cm-1 (O–H stretching), 3000–2500 
cm-1 (aliphatic stretching), 1800–1390 cm-1 (C–O stretching), 1250–
800 cm−1 (fingerprint region for polysaccharide), and under 800 cm-1 
(not considered for polysaccharides). 
In the first region, the absorption at 3800–3000 cm-1 can be seen as 
a vibration of O−H stretching from β-D-mannuronic acid and α-L-
(1–4)-guluronic acid in sodium alginate. The strong vibration stretch 
of O–H from pectin for intermolecular and intramolecular of a 
hydrogen bond from α-D-galacturonic acid appears at 3700–3000 
cm-1. During the blending process, the vibrational mode of these 
polymers shifted slightly towards the lower wavenumber due to this 
intermolecular hydrogen bonding. Thermodynamically, this 
intermolecular interaction was favored due to the free energy of the 
molecules combined with the alginate-pectin as compared to its 
individual polymer [18]. The interaction between alginate and 
pectin causes a slight shifting of the aliphatic band from 2941 cm-1 in 
pectin to 2946 cm-1. The FTIR spectra of carbonyl ester (COCH3) and 
the asymmetric stretching in the carboxylic ion (COO-) in pectin 
appear at 1740 and 1673 cm-1 [19], while the symmetric stretches of 
carboxylic and scissors vibration of acetyl and methoxy groups 
appear at 1435 and 1344 cm-1.  
At the sodium alginate spectrum, bands at 1600 and 1414 cm-1 from 
CO stretching due to asymmetric and symmetric COO-ion, 
respectively. In fig. 1, the stretching vibration of the esterified 
carboxyl in pectin at 1740 cm-1 disappears in the AP beads. The de-
esterification of the ester carbonyl group forms stable hydrogen 
bonds between the OH group, the COO-ion, and the Na+or Ca2+ion to 
create the egg-box structure [20]. The de-esterification process also 
proves by the disappearance band of pectin at 1210 cm-1 in AP refers 
to CO asymmetric stretch. The increasing intensity and sharpness of 
the AP band at 1614 cm-1 indicates a stronger hydrogen bond 
between the polymers. A new band appears in the AP spectrum that 
is the symmetric stretching of CO because of the COO ion at 
wavenumber 1436 and 1337 cm-1. This stretching vibration is 
absent in individual polymers and proves that new COO groups form 
after the de-esterification process. There is a band at 1250–1050 cm-
1 for the C–O–C stretch related to the glycoside bond of the 
biopolymer for the entire spectrum [18]. 
 
 
Fig. 1: FTIR spectra of a) bromelain, b) pectin, c) bromelain-loaded pectin, d) alginate, e) bromelain-loaded alginate, f) alginate-pectin, g) 
bromelain-loaded alginate-pectin 
 
Beads size, density, morphological surface analysis 
Uniformity, density, and sphericality of the bead size play crucial 
roles in drug release behavior in the GI tract. The composition of the 
polymer affects the bead size and density. Based on table 2, 
individual pectin beads are the smallest in size and density, followed 
by alginate beads. The AP beads with higher amounts of pectin are 
also bigger. The density of the beads decreases as the number of 
pectin increases. As seen in the morphological analysis in fig. 2, 
alginate has a spherical form while pectin and AP have little tails on 
the tips of the spheres that are created through the dropping of the 
polymer solution into the calcium chloride solution. The surfaces of 
those beads are very rough, which affects the strength of the beads 
in the dissolution medium. 
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Table 2: Bead size, density, and encapsulation efficiency of bromelain 
Beads Ratios CaCl2 (%) Bead size*a (µm) Density*b (g/cm3) Encapsulation efficiency*c 
(%) Alg Pec 
Alg 3 0 5 1031.51±38.53 1.31±0.05 82.70±0.54 
Pec 5 0 5 963.99±76.13 1.05±0.03 91.39±1.86 
AP 91 9 1 5 1167.81±82.36 1.28±0.09 83.10±0.72 
AP 51 5 1 5 1176.48±70.49 1.22±0.06 84.05±0.73 
AP 21 2 1 5 1279.46±90.61 1.18±0.03 86.31±2.00 
AP 11 1 1 5 1298.67±87.90 1.16±0.07 87.00±1.01 
AP 12 1 2 5 1304.17±78.56 1.13±0.05 88.60±1.19 
AP 15 1 5 5 1320.54±92.02 1.09±0.08 88.78±1.11 
AP 19 1 9 5 1379.00±107.84 1.08±0.06 90.07±0.56 
Alg, AP91–AP21: Total concentration of polymer 3% (w/v)  
Pec, AP11–AP19: Total concentration of polymer 5% (w/v)  
*Data represented as mean±SD, an=100, bn=30, cn=3 
 
 
Fig. 2: SEM micrographs of a) bromelain-loaded alginate beads with magnification 100× b) 1000×; c) bromelain-loaded pectin beads with 
magnification 70×, d) 1000×; e) bromelain-loaded AP beads with magnification 90×, f) 1000× 
 
Thermal analysis of bromelain-loaded beads 
Fig. 3 shows thermograms of bromelain, bromelain-loaded alginate, 
pectin, and AP complex beads. The endothermic peak appears at 
128.69 °C for bromelain and 182.49 °C for pectin. While at the 
178.16 and 296.26 °C assign as endothermic and exothermic peaks 
for alginate, respectively. A slight difference in AP occurs that 
endothermic and exothermic peaks appear at 188.93 and 297.36 °C. 
The bromelain peak was absent in biopolymer thermograms which 
confirms the complete entrapment of the bromelain [14]. 
  
 
Fig. 3: DSC thermogram of a) bromelain, b) bromelain-loaded pectin, c) bromelain-loaded alginate, and d) bromelain-loaded AP beads 
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Determination of the swelling ratio 
In the swelling medium 0.1 N HCl, the pH medium below to pKa of 
alginate (3.38–3.65) [21] and pectin (3.5–4.5) [22], the carboxylic acid 
of alginate and pectin chain is in the non-ionized form (–COOH) so that 
the structure of the beads is insoluble in the medium. The swelling 
properties of the beads are relatively low in an acidic medium. The 
phosphate buffer medium has a pH of 6.8, which higher than its pKa. In 
that condition, the alginate and pectin structures have an ionized form 
(COO-) so that there are repulsion forces between molecules with the 
same ionic charge [23]. The higher the amount of pectin, the higher the 
swelling ratios of the beads (fig. 4). 
 
 
Fig. 4: Swelling ratios of various polymer composition beads. *Data represented as mean±SD (n=3) 
 
Encapsulation efficiency, dissolution profile, and kinetics study  
Table 2 shows that the encapsulation efficiency of bromelain in 
beads was increased as the amount of pectin increased. While fig. 1 
shows that there is no interaction between bromelain and 
biopolymer of beads. There is no difference in terms of peaks on the 
FTIR spectrum before and after encapsulation; the interaction is in 
the hydrogen bond only [14].  
The formula of beads used for in vitro dissolution was chosen 
considering encapsulation efficiency and swelling ratios in the 
medium. Pectin and AP 19 were chosen for in vitro dissolution based 
on that data. The profile of the in vitro dissolution data is shown in 
fig. 5. The bromelain release in the 0.1 N HCl medium was higher in 
pectin than in AP19. The dissolution in the phosphate buffer 
medium (pH 6.8) of pectin was also higher than in AP19. Kinetics 
data shows that pectin and AP19 dissolution kinetics follows zero-
order models with a non-Fickian mechanism of release. The non-
Fickian transport means that the release processes occur through a 
combination of diffusion and erosion of the matrix beads. In the 0.1 
N HCl medium, the release of AP19 is more controlled until it moves 
into the phosphate buffer medium. 
 
 
Fig. 5: The dissolution profile of bromelain from pectin and 
AP19
  
Table 3: Kinetics model fitting of in vitro bromelain release studies 
Beads Parameter Models 
Dissolution kinetics Dissolution mechanism 
Zero-order First-order Higuchi Korsmeyer-peppas 
Pectin R2 0.7659 0.6433 0.6737 0.9165 Non-Fickian 
K 0.6483 0.0244 10.358 1.1860 
n - - - 0.6034 0.43<n<0.89 
AP19 R2 0.7095 0.6479 0.6061 0.7745 Non-Fickian 
K 0.5459 0.0115 8.5947 0.6554 
n - - - 0.5192 0.43<n<0.89 
 
In vitro antiplatelet activity 
This method compares the decrease of plasma solution absorbance 
given the presence of the sample before and after the addition of the 
aggregator compound. When the aggregator was added to the 
system, the platelet will create some aggregates and suspend them 
so that the absorbance was decreased. Significant decreases of 
absorbance are related to its worst activity as an antiplatelet agent. 
In this research, the percentage of aggregation from the negative 
control is considered a reference for determining antiplatelet 
activity. Based on fig. 6, in vitro antiplatelet activity of dialysis 
fraction is the highest (56.04%) than other bromelain fraction, but 
still lower than cilostazol (98.05%) and aspirin (96.76%) as a 
commercial drug. The aliquot fractions of the dissolution process 
still show in vitro antiplatelet activity, although not at the same level 
as the dialysis fraction.  
This result trend is in line with the previous study [12]. The 
mechanism of aspirin as an antiplatelet prodrug is by inhibiting the 
cyclooxygenase I (COX-I), which plays a role in converting 
arachidonic acid to prostaglandin H2 (PGH2). Also, PGH2 will 
further change into thromboxane A2 (TXA2) by using the 
thrombokinase enzyme to activate other platelets and promote the 
aggregation process. Meanwhile, cilostazol inhibits 
phosphodiesterase 3, which has a function to convert cyclic 
adenosine monophosphate (cAMP) to adenosine monophosphate 
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(AMP). This reduction in conversion results in inhibition of platelet 
activation and smooth muscle cell relaxation [24]. The mechanism of 
bromelain as an antiplatelet agent correlates with its proteolytic 
activity. Besides, based on other in vitro studies, bromelain is known 
to prevent thrombin-induced platelet aggregation and prevent 
platelet adhesion to endothelial cells [25]. 
 
 
Fig. 6: Antiplatelet activity of each purification step and dissolution aliquots. *Data represented as mean±SD (n=3) 
 
CONCLUSION 
The dialysis fraction has the highest specific activity of bromelain 
fraction compared to others so that this fraction will use in the 
encapsulation study. The ideal bromelain carrier was formulated 
using various compositions of alginate and pectin to study their 
physical properties. Based on the swelling and encapsulation 
efficiency data, pectin and AP19 were chosen for in vitro release. The 
kinetics data showed that the bromelain in both beads followed 
either a zero-order model with a non-Fickian release mechanism or 
a combination of diffusion and erosion. The aliquots of the 
dissolution process still showed antiplatelet activity in vitro. 
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